Oppenheimer maintains Palvella Therapeutics at Outperform, raises price target to $232 from $210
Alpha Vantage · TradingView · · AI-summarised by FinFlash
Oppenheimer has reiterated an Outperform rating for Palvella Therapeutics and increased its price target from $210 to $232, suggesting a 47.9% upside from its previous close. This adjustment aligns with other recent analyst actions, which have set price targets for Palvella Therapeutics between $240 and $246 over the last 30 days.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.